FAQs
What is the role of nutrition in managing SCD?
Nutrition plays a supportive role in managing sickle cell disease by helping maintain overall health and reducing complications. Adequate intake of folate, vitamins, and minerals supports red blood cell production, while proper hydration helps prevent vaso-occlusive crises. Balanced diets rich in fruits, vegetables, and proteins also help counter inflammation and oxidative stress associated with the disease.
What are the specific transition challenges for adolescents moving from pediatric to adult care?
Adolescents with sickle cell disease often face difficulties when transitioning from pediatric to adult healthcare systems. Pediatric care is usually highly coordinated, while adult care requires greater patient independence. Young adults must learn to manage medications, appointments, and symptoms themselves, while also coping with academic, social, and emotional challenges during this period.
Can people with sickle cell disease exercise safely?
People with sickle cell disease can usually exercise safely, but activities should be moderate and carefully monitored. Adequate hydration, gradual warm-ups, and avoiding extreme temperatures are important to reduce the risk of triggering a vaso-occlusive crisis. Low- to moderate-intensity activities such as walking or swimming are generally encouraged to support cardiovascular health.
Reference
1. Rees, D. C., Williams, T. N., & Gladwin, M. T. (2010). Sickle-cell disease. The Lancet, 376(9757), 2018-2031.
2. Chaturvedi, S., Ghafuri, D. L., Jordan, N., et al. (2018). Clustering of end‐organ disease and earlier mortality in adults with sickle cell disease: A retrospective‐prospective cohort study. American journal of hematology, 93(9), 1153-1160.
3. Chies, J. A. B., & Nardi, N. B. (2001). Sickle cell disease: a chronic inflammatory condition. Medical hypotheses, 57(1), 46-50.
4. Noronha, S., Sadreameli, S. C., & Strouse, J. J. (2016). Management of sickle cell disease in children. Southern medical journal, 109(9), 495.
5. Carden, M. A., & Little, J. (2019). Emerging disease-modifying therapies for sickle cell disease. Haematologica, 104(9), 1710.
6. El-Hazmi, M. A., Al-Hazmi, A. M., & Warsy, A. S. (2011). Sickle cell disease in Middle East Arab countries. The Indian Journal of Medical Research, 134(5), 597.
7. Hemminki, K., Li, X., Försti, A., et al. (2015). Thalassemia and sickle cell anemia in Swedish immigrants: genetic diseases have become global. SAGE open medicine, 3, 2050312115613097.
8. Piel, F. B., Patil, A. P., Howes, R. E., et al. (2010). Global distribution of the sickle cell gene and geographical confirmation of the malaria hypothesis. Nature communications, 1(1), 104.
9. Minkovitz, C. S., Grason, H., Ruderman, M., et al. (2016). Newborn screening programs and sickle cell disease: a public health services and systems approach. American journal of preventive medicine, 51(1), S39-S47.
10. Davies, E. G., Hirst, C., Lottenberg, R., et al. (2004). Pneumococcal vaccines for sickle cell disease. Cochrane Database of Systematic Reviews, (1).
11. Reeves, S. L., Tribble, A. C., Madden, B., et al. (2018). Antibiotic prophylaxis for children with sickle cell anemia. Pediatrics, 141(3), e20172182.
12. Mburu, J., & Odame, I. (2019). Sickle cell disease: Reducing the global disease burden. International journal of laboratory hematology, 41, 82-88.
13. Alapan, Y., Fraiwan, A., Kucukal, E., et al. (2016). Emerging point-of-care technologies for sickle cell disease screening and monitoring. Expert review of medical devices, 13(12), 1073-1093.
14. Higgs, D. R., & Wood, W. G. (2008). Genetic complexity in sickle cell disease. Proceedings of the National Academy of Sciences, 105(33), 11595-11596.
15. Noguchi, C. T., & Schechter, A. N. (1981). The intracellular polymerization of sickle hemoglobin and its relevance to sickle cell disease. Blood, 58(6), 1057-1068.
16. Li, X., Dao, M., Lykotrafitis, G., et al. (2017). Biomechanics and biorheology of red blood cells in sickle cell anemia. Journal of biomechanics, 50, 34-41.
17. Sturgeon, P., Itano, H. A., & Valentine, W. N. (1952). Chronic hemolytic anemia associated with thalassemia and sickling traits. Blood, 7(3), 350-357.
18. Setty, B. N., & Stuart, M. J. (1996). Vascular cell adhesion molecule-1 is involved in mediating hypoxia-induced sickle red blood cell adherence to endothelium: potential role in sickle cell disease. Blood, 88(6), 2311-2320.
19. Ofori-Acquah, S. F. (2020). Sickle cell disease as a vascular disorder. Expert Review of Hematology, 13(6), 645-653.
20. Uwaezuoke, S. N., Ayuk, A. C., Ndu, I. K., et al. (2018). Vaso-occlusive crisis in sickle cell disease: current paradigm on pain management. Journal of pain research, 11(2018), 3141-3150.
21. Nader, E., Romana, M., & Connes, P. (2020). The red blood cell—inflammation vicious circle in sickle cell disease. Frontiers in immunology, 11, 454.
22. Kato, G. J., Gladwin, M. T., & Steinberg, M. H. (2007). Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood reviews, 21(1), 37-47.
23. Kim-Shapiro, D. B., & Gladwin, M. T. (2018). Nitric oxide pathology and therapeutics in sickle cell disease. Clinical hemorheology and microcirculation, 68(2-3), 223-237.
24. Bunn, H. F., Nathan, D. G., Dover, G. J., et al. (2010). Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood, The Journal of the American Society of Hematology, 116(5), 687-692.
25. Nur, E., Biemond, B. J., Otten, H. M., et al. (2011). Oxidative stress in sickle cell disease; pathophysiology and potential implications for disease management. American journal of hematology, 86(6), 484-489.
26. Man, Y., Sekyonda, Z., Monchamp, K., et al. (2021). Hypoxia impact on red blood cell-mediated microvascular occlusion and adhesion in sickle cell disease and sickle cell trait. Blood, 138, 966.
27. Novelli, E. M., & Gladwin, M. T. (2016). Crises in sickle cell disease. Chest, 149(4), 1082-1093.
28. Farooq, S., & Testai, F. D. (2019). Neurologic complications of sickle cell disease. Current neurology and neuroscience reports, 19(4), 17.
29. Brousse, V., Buffet, P., & Rees, D. (2014). The spleen and sickle cell disease: the sick (led) spleen. British journal of haematology, 166(2), 165-176.
30. Marti-Carvajal, A. J., & Agreda-Perez, L. H. (2019). Antibiotics for treating osteomyelitis in people with sickle cell disease. Cochrane Database of Systematic Reviews, (10).
31. Nath, K. A., & Hebbel, R. P. (2015). Sickle cell disease: renal manifestations and mechanisms. Nature Reviews Nephrology, 11(3), 161-171.
32. Voskaridou, E., Christoulas, D., & Terpos, E. (2012). Sickle‐cell disease and the heart: review of the current literature. British journal of haematology, 157(6), 664-673.
33. Alshurafa, A., Soliman, A. T., De Sanctis, V., et al. (2023). Clinical and epidemiological features and therapeutic options of avascular necrosis in patients with sickle cell disease (SCD): a cross-sectional study. Acta Bio Medica: Atenei Parmensis, 94(5), e2023198.
34. Nelson, M., Noisette, L., Pugh, N., et al. (2024). The clinical spectrum of HbSC sickle cell disease‐not a benign condition. British journal of haematology, 205(2), 653-663.
35. Notarangelo, L. D., Agostini, A., Casale, M., et al. (2020). HbS/β+ thalassemia: really a mild disease? A national survey from the AIEOP sickle cell disease study group with genotype‐phenotype correlation. European Journal of Haematology, 104(3), 214-222.
36. Steinberg, M. H. (2020). Fetal hemoglobin in sickle cell anemia. Blood, The Journal of the American Society of Hematology, 136(21), 2392-2400.
37. Agrawal, R. K., Patel, R. K., Shah, V., et al. (2014). Hydroxyurea in sickle cell disease: drug review. Indian Journal of Hematology and Blood Transfusion, 30(2), 91-96.
38. Howard, J. (2016). Sickle cell disease: when and how to transfuse. Hematology 2014, the American Society of Hematology Education Program Book, 2016(1), 625-631.
39. Linder, G. E., & Chou, S. T. (2021). Red cell transfusion and alloimmunization in sickle cell disease. haematologica, 106(7), 1805.
40. Vichinsky, E., Hoppe, C. C., Ataga, K. I., et al. (2019). A phase 3 randomized trial of voxelotor in sickle cell disease. New England Journal of Medicine, 381(6), 509-519.
41. Ataga, K. I., Kutlar, A., Kanter, J., et al. (2017). Crizanlizumab for the prevention of pain crises in sickle cell disease. New England Journal of Medicine, 376(5), 429-439.
42. Niihara, Y., Miller, S. T., Kanter, J., et al. (2018). A phase 3 trial of l-glutamine in sickle cell disease. New England Journal of Medicine, 379(3), 226-235.
43. Hsieh, M. M., Kang, E. M., Fitzhugh, C. D., et al. (2009). Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. New England Journal of Medicine, 361(24), 2309-2317.
44. Park, S. H., & Bao, G. (2021). CRISPR/Cas9 gene editing for curing sickle cell disease. Transfusion and Apheresis Science, 60(1), 103060.
45. Urbinati, F., Campo Fernandez, B., Masiuk, K. E., et al. (2018). Gene therapy for sickle cell disease: a lentiviral vector comparison study. Human gene therapy, 29(10), 1153-1166.
46. Elsabagh, A. A., Elhadary, M., Elsayed, B., et al. (2023). Artificial intelligence in sickle disease. Blood Reviews, 61, 101102.
47. Johnson, A., Yang, F., Gollarahalli, S., et al. (2019). Use of mobile health apps and wearable technology to assess changes and predict pain during treatment of acute pain in sickle cell disease: feasibility study. JMIR mHealth and uHealth, 7(12), e13671.
48. Schatz, J., Finke, R. L., Kellett, J. M., et al. (2002). Cognitive functioning in children with sickle cell disease: a meta-analysis. Journal of pediatric psychology, 27(8), 739-748.
49. Smith, M., & Praetorius, R. T. (2015). The challenges and opportunities associated with sickle cell disease prevention, education, and management. Social Work in Public Health, 30(7), 592-612.
50. Anie, K. A. (2024). The intersection of sickle cell disease, stigma, and pain in Africa. Hematology, 2024(1), 240-245.